78.21
Illumina Inc stock is traded at $78.21, with a volume of 3.76M.
It is down -2.60% in the last 24 hours and up +4.20% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$80.30
Open:
$80.3
24h Volume:
3.76M
Relative Volume:
1.47
Market Cap:
$12.09B
Revenue:
$4.34B
Net Income/Loss:
$-965.00M
P/E Ratio:
-12.88
EPS:
-6.07
Net Cash Flow:
$869.00M
1W Performance:
+2.44%
1M Performance:
+4.20%
6M Performance:
-45.02%
1Y Performance:
-32.33%
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ILMN
Illumina Inc
|
78.21 | 12.09B | 4.34B | -965.00M | 869.00M | -6.07 |
![]()
TMO
Thermo Fisher Scientific Inc
|
406.05 | 153.96B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
187.82 | 138.19B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
509.42 | 39.13B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
111.52 | 30.65B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
141.82 | 26.52B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-04-25 | Reiterated | Citigroup | Neutral |
Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
Aug-28-24 | Upgrade | Argus | Hold → Buy |
Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
Jun-03-24 | Resumed | Jefferies | Hold |
Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-14-23 | Initiated | Stephens | Overweight |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Sep-28-23 | Initiated | Bernstein | Underperform |
Jul-05-23 | Resumed | JP Morgan | Neutral |
Jan-25-23 | Downgrade | Argus | Buy → Hold |
Jan-05-23 | Initiated | Scotiabank | Sector Perform |
Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-18-22 | Upgrade | Stifel | Hold → Buy |
Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
Mar-03-21 | Initiated | Barclays | Underweight |
Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Sep-22-20 | Downgrade | Stifel | Buy → Hold |
Sep-22-20 | Downgrade | UBS | Buy → Neutral |
Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jan-08-20 | Initiated | Wells Fargo | Underweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-15-19 | Initiated | Stifel | Buy |
Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina Inc (ILMN) CEO Jacob Thaysen Increases Stake with Recen - GuruFocus
Illumina Leadership to Share Strategic Vision at Prestigious Bernstein Conference May 28 - Stock Titan
Illumina unveils DRAGEN version 4.4 software focusing on oncology applications for clinical research - BioSpectrum India
Illumina, Inc. (ILMN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey
South East Asia Molecular Diagnostics Market Forecast to 2031: PCR Technology Leads Growth, Kits & Reagents Hold Largest Share - GlobeNewswire Inc.
Onco-hematology Molecular Testing Market Top Players - openPR.com
Championing greater health in and outside the office - Illumina
NGS Library Preparation Market Growth Projections | Key Players: Illumina, Thermo Fisher Scientific, Roche - openPR.com
Illumina unveils DRAGEN v4.4 with enhanced accuracy - Investing.com
Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications - Illumina
Investing in Illumina (ILMN)? Don't Miss Assessing Its International Revenue Trends - Yahoo Finance
Illumina, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Illumina, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Illumina Faces Uncertainties From China Ban, Research Slump, Morgan Stanley Says - marketscreener.com
Morgan Stanley Adjusts Illumina Price Target to $100 From $136, Maintains In Line Rating - marketscreener.com
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Canaccord cuts Illumina stock target to $87, maintains hold By Investing.com - Investing.com India
Canaccord cuts Illumina stock target to $87, maintains hold - Investing.com
Illumina Q1 2025 revenue down 1% to USD 1.04 billion - Medical Buyer
Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions - MSN
Illumina: Multiple Headwinds Point To Limited Upside In 2025 (NASDAQ:ILMN) - Seeking Alpha
Illumina (ILMN) Faces Adjusted Price Target and Positive Earnings Outlook | ILMN Stock News - GuruFocus
Illumina, Inc. (NASDAQ:ILMN) Q1 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera - Investing.com
Cathie Wood’s ARK buys Shopify, Illumina stock; sells Palantir, Natera By Investing.com - Investing.com India
Illumina (ILMN) Price Target Lowered by JP Morgan | ILMN Stock N - GuruFocus
SEC ends probe of Illumina’s Grail acquisition - MedTech Dive
TD Cowen raises Illumina stock target to $89, maintains Hold rating - Investing.com
Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina, Merck, AstraZeneca, and Roche Dominate with their Contributions to Research, Product Approvals, and Partnerships - GlobeNewswire
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips - Yahoo Finance
Illumina Q1 2025 slides: Revises guidance downward amid China restrictions and tariff impacts - Investing.com
Lab-on-a-Chip Market Insights: Growth, Trends & Forecast - openPR.com
Illumina Inc (ILMN) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
Earnings call transcript: Illumina Q1 2025 beats EPS forecast but faces stock dip - Investing.com
Illumina Reports Q1 2025 Financial Results Amid Challenges - TipRanks
Illumina: Q1 Earnings Snapshot - Norwalk Hour
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Illumina confirms SEC has closed investigation into $8B Grail deal - Endpoints News
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (ILMN) Shares Drop 3% Despite Beating Q1 EPS Estimates - GuruFocus
Illumina’s (NASDAQ:ILMN) Q1 Sales Top Estimates - Yahoo Finance
Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat - MSN
Illumina Cuts Guidance on Threat From Tariffs and China Ban - Bloomberg
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 - PR Newswire
Lobbying Update: $620,000 of ILLUMINA INC. lobbying was just disclosed - Nasdaq
Clinical Oncology Next-Generation Sequencing Market Size, - openPR.com
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Single Cell Genome Sequencing Market Deep Research 2025-2032 | - openPR.com
ILLUMINA Earnings Preview: Recent $ILMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Here’s Why Artisan Mid Cap Fund Decided to Exit Illumina (ILMN) - Insider Monkey
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):